



## General description

Mercaptopurine is a purine antimetabolite antineoplastic agent used in treatment protocols for various leukaemias and lymphomas.

|                    |   |
|--------------------|---|
| INN                | Mercaptopurine  |
| ATC codes          | L01BB02   |
| Medicine type      | Chemical agent  |
| EML status history | First added in 1984 (TRS 722) for <b>Unspecified malignant neoplasms of ill-defined or unspecified sites</b><br>Added in 2015 (TRS 994) for <b>Lymphoid leukaemia, not elsewhere classified</b><br>Added in 2015 (TRS 994) for <b>Acute myeloid leukaemia with recurrent genetic abnormalities</b><br>Removed in 2015 (TRS 994) for <b>Unspecified malignant neoplasms of ill-defined or unspecified sites</b><br>Added in 2023 (TRS 1049) for <b>Langerhans cell histiocytosis</b> |
| Wikipedia          | <a href="#">Mercaptopurine</a>   |
| DrugBank           | <a href="#">Mercaptopurine</a>   |

## Recommendations

Section Cytotoxic medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 50 mg tablet

### Indications

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Unspecified malignant neoplasms of ill-defined or unspecified sites

Langerhans cell histiocytosis

